BioDelivery Sciences International Inc. (BDSI) Sees Large Volume Increase
Shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) saw strong trading volume on Thursday . 935,115 shares traded hands during mid-day trading, an increase of 43% from the previous session’s volume of 651,966 shares.The stock last traded at $2.69 and had previously closed at $2.46.
A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a report on Saturday, July 9th. FBR & Co upped their price target on shares of BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, May 4th. Zacks Investment Research cut shares of BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a report on Friday, May 6th. Piper Jaffray Cos. restated an “overweight” rating and set a $4.00 price target (down from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Finally, Janney Montgomery Scott restated a “hold” rating and set a $4.00 price target on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.25.
The company’s 50-day moving average price is $2.46 and its 200 day moving average price is $2.98. The company’s market capitalization is $151.14 million.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) EPS for the quarter, hitting analysts’ consensus estimates of ($0.31). During the same quarter in the previous year, the business earned ($0.37) earnings per share. The company had revenue of $5 million for the quarter, compared to analyst estimates of $3.35 million. The company’s revenue was up 194.1% on a year-over-year basis. On average, equities research analysts forecast that BioDelivery Sciences International Inc. will post ($1.16) EPS for the current fiscal year.
In other BioDelivery Sciences International news, Director William B. Stone sold 16,000 shares of BioDelivery Sciences International stock in a transaction on Thursday, August 11th. The shares were sold at an average price of $2.57, for a total value of $41,120.00. Following the sale, the director now directly owns 122,675 shares in the company, valued at approximately $315,274.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
A hedge fund recently raised its stake in BioDelivery Sciences International stock. Bank of Montreal Can raised its stake in shares of BioDelivery Sciences International Inc. (NASDAQ:BDSI) by 3.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 829,056 shares of the specialty pharmaceutical company’s stock after buying an additional 28,838 shares during the period. Bank of Montreal Can owned about 1.57% of BioDelivery Sciences International worth $3,971,000 at the end of the most recent quarter.
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.